MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas

Research output: Contribution to journal › Review › Research › peer-review

Standard

MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas. / Gluud, Maria; Willerslev-Olsen, Andreas; Gjerdrum, Lise Mette Rahbek; Lindahl, Lise M.; Buus, Terkild B.; Andersen, Mads Hald; Bonefeld, Charlotte Menne; Krejsgaard, Thorbjorn; Litvinov, Ivan V.; Iversen, Lars; Becker, Jürgen C.; Persson, Jenny L.; Koralov, Sergei B.; Litman, Thomas; Geisler, Carsten; Woetmann, Anders; Odum, Niels.

In: Cancers, Vol. 12, No. 5, 1229, 2020.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Gluud, M, Willerslev-Olsen, A, Gjerdrum, LMR, Lindahl, LM, Buus, TB, Andersen, MH, Bonefeld, CM, Krejsgaard, T, Litvinov, IV, Iversen, L, Becker, JC, Persson, JL, Koralov, SB, Litman, T, Geisler, C, Woetmann, A & Odum, N 2020, 'MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas', Cancers, vol. 12, no. 5, 1229. https://doi.org/10.3390/cancers12051229

APA

Gluud, M., Willerslev-Olsen, A., Gjerdrum, L. M. R., Lindahl, L. M., Buus, T. B., Andersen, M. H., Bonefeld, C. M., Krejsgaard, T., Litvinov, I. V., Iversen, L., Becker, J. C., Persson, J. L., Koralov, S. B., Litman, T., Geisler, C., Woetmann, A., & Odum, N. (2020). MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas. Cancers, 12(5), [1229]. https://doi.org/10.3390/cancers12051229

Vancouver

Gluud M, Willerslev-Olsen A, Gjerdrum LMR, Lindahl LM, Buus TB, Andersen MH et al. MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas. Cancers. 2020;12(5). 1229. https://doi.org/10.3390/cancers12051229

Author

Gluud, Maria ; Willerslev-Olsen, Andreas ; Gjerdrum, Lise Mette Rahbek ; Lindahl, Lise M. ; Buus, Terkild B. ; Andersen, Mads Hald ; Bonefeld, Charlotte Menne ; Krejsgaard, Thorbjorn ; Litvinov, Ivan V. ; Iversen, Lars ; Becker, Jürgen C. ; Persson, Jenny L. ; Koralov, Sergei B. ; Litman, Thomas ; Geisler, Carsten ; Woetmann, Anders ; Odum, Niels. / MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas. In: Cancers. 2020 ; Vol. 12, No. 5.

Bibtex

@article{13d119d12aca487e8b2b965ecba28d54,
title = "MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas",
abstract = "Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of potentially devastating primary skin malignancies. Despite decades of intense research efforts, the pathogenesis is still not fully understood. In the early stages, both clinical and histopathological diagnosis is often difficult due to the ability of CTCL to masquerade as benign skin inflammatory dermatoses. Due to a lack of reliable biomarkers, it is also difficult to predict which patients will respond to therapy or progress towards severe recalcitrant disease. In this review, we discuss recent discoveries concerning dysregulated microRNA (miR) expression and putative pathological roles of oncogenic and tumor suppressive miRs in CTCL. We also focus on the interplay between miRs, histone deacetylase inhibitors, and oncogenic signaling pathways in malignant T cells as well as the impact of miRs in shaping the inflammatory tumor microenvironment. We highlight the potential use of miRs as diagnostic and prognostic markers, as well as their potential as therapeutic targets. Finally, we propose that the combined use of miR-modulating compounds with epigenetic drugs may provide a novel avenue for boosting the clinical efficacy of existing anti-cancer therapies in CTCL.",
keywords = "Biomarker, Cancer, Ctcl, Cutaneous t-cell lymphoma, Microrna, Mir, Mycosis fungoides, Oncogene, Targeted therapy, Tumor suppressor",
author = "Maria Gluud and Andreas Willerslev-Olsen and Gjerdrum, {Lise Mette Rahbek} and Lindahl, {Lise M.} and Buus, {Terkild B.} and Andersen, {Mads Hald} and Bonefeld, {Charlotte Menne} and Thorbjorn Krejsgaard and Litvinov, {Ivan V.} and Lars Iversen and Becker, {J{\"u}rgen C.} and Persson, {Jenny L.} and Koralov, {Sergei B.} and Thomas Litman and Carsten Geisler and Anders Woetmann and Niels Odum",
year = "2020",
doi = "10.3390/cancers12051229",
language = "English",
volume = "12",
journal = "Cancers",
issn = "2072-6694",
publisher = "M D P I AG",
number = "5",

}

RIS

TY - JOUR

T1 - MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas

AU - Gluud, Maria

AU - Willerslev-Olsen, Andreas

AU - Gjerdrum, Lise Mette Rahbek

AU - Lindahl, Lise M.

AU - Buus, Terkild B.

AU - Andersen, Mads Hald

AU - Bonefeld, Charlotte Menne

AU - Krejsgaard, Thorbjorn

AU - Litvinov, Ivan V.

AU - Iversen, Lars

AU - Becker, Jürgen C.

AU - Persson, Jenny L.

AU - Koralov, Sergei B.

AU - Litman, Thomas

AU - Geisler, Carsten

AU - Woetmann, Anders

AU - Odum, Niels

PY - 2020

Y1 - 2020

N2 - Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of potentially devastating primary skin malignancies. Despite decades of intense research efforts, the pathogenesis is still not fully understood. In the early stages, both clinical and histopathological diagnosis is often difficult due to the ability of CTCL to masquerade as benign skin inflammatory dermatoses. Due to a lack of reliable biomarkers, it is also difficult to predict which patients will respond to therapy or progress towards severe recalcitrant disease. In this review, we discuss recent discoveries concerning dysregulated microRNA (miR) expression and putative pathological roles of oncogenic and tumor suppressive miRs in CTCL. We also focus on the interplay between miRs, histone deacetylase inhibitors, and oncogenic signaling pathways in malignant T cells as well as the impact of miRs in shaping the inflammatory tumor microenvironment. We highlight the potential use of miRs as diagnostic and prognostic markers, as well as their potential as therapeutic targets. Finally, we propose that the combined use of miR-modulating compounds with epigenetic drugs may provide a novel avenue for boosting the clinical efficacy of existing anti-cancer therapies in CTCL.

AB - Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of potentially devastating primary skin malignancies. Despite decades of intense research efforts, the pathogenesis is still not fully understood. In the early stages, both clinical and histopathological diagnosis is often difficult due to the ability of CTCL to masquerade as benign skin inflammatory dermatoses. Due to a lack of reliable biomarkers, it is also difficult to predict which patients will respond to therapy or progress towards severe recalcitrant disease. In this review, we discuss recent discoveries concerning dysregulated microRNA (miR) expression and putative pathological roles of oncogenic and tumor suppressive miRs in CTCL. We also focus on the interplay between miRs, histone deacetylase inhibitors, and oncogenic signaling pathways in malignant T cells as well as the impact of miRs in shaping the inflammatory tumor microenvironment. We highlight the potential use of miRs as diagnostic and prognostic markers, as well as their potential as therapeutic targets. Finally, we propose that the combined use of miR-modulating compounds with epigenetic drugs may provide a novel avenue for boosting the clinical efficacy of existing anti-cancer therapies in CTCL.

KW - Biomarker

KW - Cancer

KW - Ctcl

KW - Cutaneous t-cell lymphoma

KW - Microrna

KW - Mir

KW - Mycosis fungoides

KW - Oncogene

KW - Targeted therapy

KW - Tumor suppressor

U2 - 10.3390/cancers12051229

DO - 10.3390/cancers12051229

M3 - Review

C2 - 32414221

AN - SCOPUS:85086278145

VL - 12

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 5

M1 - 1229

ER -

ID: 243338865